CREBZF Antibody

What is CREBZF and what are its key cellular functions?

CREBZF (CREB/ATF bZIP transcription factor) is a member of the mammalian ATF/CREB family of transcription factors that contains a basic leucine zipper (bZIP) domain. It functions primarily as a transcriptional regulator with several critical roles. CREBZF strongly activates transcription when bound to Host Cell Factor C1 (HCFC1) . Importantly, CREBZF has been identified as a novel positive regulator of the tumor suppressor p53, where it interacts with both HEY1 (a known p53 activator) and p53 itself . CREBZF expression stabilizes and activates p53, enhancing p53 transcriptional activity synergistically with HEY1 . Additionally, CREBZF suppresses the expression of Herpes Simplex Virus (HSV) proteins in infected cells in an HCFC1-dependent manner and can down-regulate expression of various cellular genes . Recent research also indicates that a CREBZF/Zhangfei isoform plays a role in activating CHOP during prolonged cellular stress .

What are the different isoforms of CREBZF and how do they influence antibody selection?

Research has identified at least two major isoforms of CREBZF: ZF-short and ZF-long . Both isoforms demonstrate the ability to activate p53-dependent transcriptional activity, although their potency varies depending on the promoter context (from 2-fold activation with the PUMA promoter to 25-fold activation with the PIG3 promoter) . When selecting antibodies for CREBZF research, it's essential to consider which isoform(s) you need to detect. Antibodies targeting regions common to both isoforms will detect total CREBZF, while isoform-specific antibodies may be required for studying differential functions. Each isoform's distinct molecular weight should be considered when interpreting Western blot results, as ZF-short and ZF-long will appear as separate bands. Additionally, recent research mentions a CREBZF/Zhangfei isoform that specifically activates CHOP during prolonged cellular stress , which may require specialized antibodies for detection.

What are the common applications for CREBZF antibodies in research?

CREBZF antibodies have multiple research applications that help elucidate its cellular functions:

These applications allow researchers to investigate CREBZF's role in p53 regulation, stress response pathways, and transcriptional control mechanisms . When using commercial antibodies like the rabbit polyclonal described in the search results, validation in your specific experimental system is crucial for reliable results.

How should I optimize Western blot protocols for CREBZF detection?

When performing Western blots to detect CREBZF, several optimization steps are essential for clear and specific detection:

What controls should I include when studying CREBZF's interaction with p53?

When investigating CREBZF's interaction with p53, several critical controls ensure experimental rigor:

• Negative controls: Use p53-null cell lines (like HCT116 p53−/− cells) to demonstrate p53-dependency of observed effects. In these cells, CREBZF fails to activate p53-responsive reporters without co-transfection of p53 .

• Positive controls: Use reporters with known p53-binding sites (like PIG3-LUC). Deletion of these binding sites (e.g., PIG3-delF) should diminish CREBZF's effects, as previously demonstrated .

• Functional verification: Monitor transcription of p53-target genes like p21 and PIG3 at both protein and mRNA levels. CREBZF expression increases both p53 and p21 protein levels but only p21 mRNA levels, indicating distinct regulatory mechanisms .

• Dose-dependency: Establish dose-response relationships by titrating CREBZF expression to demonstrate specificity.

• RNA interference controls: Partial depletion of endogenous CREBZF has been shown to diminish p53 protein levels and inhibit HEY1-mediated activation of p53 , providing a valuable negative control approach.

How can I accurately assess CREBZF's impact on cellular responses to stress?

CREBZF has been implicated in various stress responses, including UV radiation and 5-fluorouracil treatment. To accurately assess its impact:

• UV radiation experiments: When evaluating CREBZF's protective effect against UV radiation, induce CREBZF expression before UVC irradiation (e.g., 24 hours prior to 30 mJ/cm² UVC exposure). Monitor cell survival over several days (e.g., 4 days post-irradiation) using appropriate cell counting or viability assays. In HCT116 cells, CREBZF expression has been shown to increase survival rates from 10% to 30% following UVC irradiation .

• Chemotherapeutic sensitivity: For 5-fluorouracil sensitivity assays, induce CREBZF expression before drug treatment and perform standard cytotoxicity assays. CREBZF expression significantly increases sensitivity to 5-fluorouracil in both U2OS and HCT116 cells .

• Molecular readouts: Assess p53 post-translational modifications (acetylation at Lys-382 and phosphorylation at Ser-15, Ser-20, and Ser-46) as these reflect CREBZF's activation of p53 signaling .

• Temporal considerations: Monitor changes in p53 protein levels at early timepoints (e.g., 4 hours following CREBZF expression) to capture immediate effects .

• Transcriptional analysis: Measure transcription of stress-responsive genes, particularly p53 targets like p21 and PIG3, using qRT-PCR to confirm functional outcomes of CREBZF activity .

How does CREBZF regulate p53 at the molecular level?

CREBZF regulates p53 through multiple molecular mechanisms:

• Post-translational modification induction: CREBZF expression strongly increases p53 acetylation at Lys-382, a modification that prevents MDM2-mediated p53 degradation . Additionally, CREBZF induces phosphorylation of p53 at multiple N-terminal residues (Ser-15, Ser-20, and Ser-46), which further stabilize and activate p53 .

• Protein stabilization: CREBZF increases p53 protein levels without affecting p53 mRNA expression, indicating post-transcriptional regulation . This stabilization can be detected as early as 4 hours after CREBZF expression.

• Transcriptional synergy: CREBZF cooperates synergistically with HEY1 to enhance p53 transcriptional activity . This synergy suggests that CREBZF may function as part of a larger transcriptional complex.

• MDM2 pathway: Unlike HEY1, which inhibits MDM2 expression, CREBZF doesn't reduce MDM2 levels, suggesting a distinct regulatory mechanism .

• p53-dependent transcription: CREBZF's activation of reporter genes requires intact p53-binding sites and functional p53 protein, as demonstrated in p53-null cells and with modified reporter constructs .

What role does CREBZF play in cancer biology and chemotherapeutic responses?

CREBZF has emerging significance in cancer biology through several mechanisms:

• Chromosomal location: In humans, CREBZF maps to chromosome band 11q14.1, a region frequently lost in various cancers including malignant melanoma, neuroblastoma, head and neck squamous cell carcinomas, chronic lymphocytic leukemia, and lung carcinoids . This genomic location hints at potential tumor-suppressive functions.

• Chemosensitivity modulation: CREBZF expression enhances sensitivity to 5-fluorouracil, a p53-activating chemotherapeutic drug that interferes with the MDM2-p53 feedback circuit . This suggests CREBZF could be a determinant of treatment response.

• p53 pathway regulation: As a positive regulator of the p53 tumor suppressor, CREBZF likely influences cellular responses to DNA damage and oncogenic stress .

• Differential drug responses: Interestingly, while CREBZF sensitizes cells to 5-fluorouracil, it doesn't affect sensitivity to other p53-activating drugs like cisplatin and doxorubicin, suggesting pathway specificity .

• Stress response integration: CREBZF's involvement in various cellular stress responses, including UV damage protection and unfolded protein response, suggests it may coordinate integrated stress responses in cancer cells .

These findings suggest that alterations in CREBZF expression or function might contribute to tumor progression and therapy resistance, making it a potential biomarker or therapeutic target in cancer research.

What technical challenges exist in studying CREBZF-HEY1-p53 interactions?

Investigating the complex interactions between CREBZF, HEY1, and p53 presents several technical challenges:

Why might I see unexpected bands on Western blots using CREBZF antibodies?

Unexpected bands on Western blots with CREBZF antibodies may arise from several sources:

• Multiple isoforms: CREBZF exists in at least two isoforms (ZF-short and ZF-long) , which will appear as distinct bands. Additional bands may represent tissue-specific or stress-induced isoforms like the CREBZF/Zhangfei variant mentioned in recent research .

• Post-translational modifications: CREBZF itself may undergo modifications that alter its mobility on SDS-PAGE. Additionally, CREBZF induces modifications in p53 (acetylation and phosphorylation) , which can affect p53's migration pattern if you're co-detecting both proteins.

• Proteolytic degradation: CREBZF may be subject to degradation during sample preparation. Ensure proper use of protease inhibitors and maintain cold conditions throughout sample handling.

• Cross-reactivity: Antibodies may cross-react with other members of the ATF/CREB family due to structural similarities in their bZIP domains. The ATF/CREB family comprises a large and heterogeneous group of transcription factors that share the ability to bind to consensus ATF/CRE sites .

• Heterodimer formation: CREBZF can form heterodimers with other ATF family members , which might be detected as higher molecular weight complexes if not fully denatured.

How can I distinguish between CREBZF's direct effects and indirect effects through p53 activation?

Distinguishing direct CREBZF effects from those mediated through p53 requires systematic experimental approaches:

• Use p53-null systems: Compare phenotypes in isogenic cell lines differing only in p53 status (e.g., HCT116 p53+/+ vs. HCT116 p53−/− cells). Effects observed only in p53-expressing cells are likely p53-dependent .

• Reporter assays with modified binding sites: Use reporters with and without p53-binding sites (e.g., PIG3-LUC vs. PIG3-delF). CREBZF-induced activation that requires intact p53-binding sites suggests p53 dependency .

• Transcriptome analysis: Compare gene expression changes induced by CREBZF in p53-competent and p53-deficient backgrounds to identify p53-dependent and p53-independent gene sets.

• Temporal analysis: p53-dependent effects often follow a specific timeline after CREBZF expression. For example, p53 protein increase can be detected within 4 hours of CREBZF expression, while changes in p53 target genes occur later .

• Domain mutants: Create CREBZF mutants that retain some functions but lose p53 interaction to separate direct transcriptional effects from p53-mediated ones.

What factors affect reproducibility in CREBZF antibody-based experiments?

Several factors can impact reproducibility when using CREBZF antibodies:

• Antibody validation: The specificity of CREBZF antibodies should be validated in your experimental system, particularly if working with different species or cell types. Commercial antibodies like the rabbit polyclonal described can be used for Western blot at 1 μg/mL and ELISA at 1:1562500 , but these concentrations should be optimized for each application.

• Expression levels: Endogenous CREBZF levels may vary significantly between cell types or under different stress conditions. Consider establishing baseline expression patterns in your system.

• Storage conditions: Antibody activity can be compromised by improper storage. The commercial antibody mentioned is lyophilized in PBS buffer with 2% sucrose and should be reconstituted with 50 μL of distilled water to a final concentration of 1 mg/mL, then aliquoted and stored at -20°C or below to avoid multiple freeze-thaw cycles .

• Cellular stress status: CREBZF functions in stress responses, including UV damage protection and unfolded protein response . Unintentional stressors during cell culture may alter CREBZF expression or localization.

• Technical considerations: Proper blocking (to minimize non-specific binding), appropriate secondary antibody dilutions (1:50,000-100,000 for HRP-conjugated secondaries in Western blot) , and consistent incubation times all contribute to reproducible results.

What are the emerging areas of CREBZF research beyond p53 regulation?

While CREBZF's regulation of p53 is well-established, several emerging research areas warrant further investigation:

• Stress response integration: CREBZF appears to participate in various cellular stress responses, including the unfolded protein response, amino acid deprivation, and DNA damage . Understanding how CREBZF coordinates these different stress pathways could reveal fundamental principles of cellular homeostasis.

• Cancer biomarker potential: Given CREBZF's chromosomal location at 11q14.1—a region frequently lost in various cancers —investigating CREBZF expression patterns across cancer types could identify potential diagnostic or prognostic biomarkers.

• Therapeutic resistance mechanisms: CREBZF's ability to modulate sensitivity to 5-fluorouracil but not other chemotherapeutics suggests pathway-specific effects . Elucidating these mechanisms could inform more personalized treatment approaches.

• Transcriptional network mapping: Beyond its interaction with p53 and HEY1, CREBZF likely participates in broader transcriptional networks. Comprehensive protein-protein interaction studies and chromatin immunoprecipitation sequencing (ChIP-seq) could map these networks.

• Isoform-specific functions: The distinct roles of ZF-short, ZF-long, and the newly identified CREBZF/Zhangfei isoform remain incompletely characterized. Isoform-specific knockout or knockdown studies could elucidate their unique contributions to cellular physiology.

How might CREBZF antibodies contribute to translational research?

CREBZF antibodies have significant potential in translational research applications:

• Cancer diagnostics: If CREBZF expression patterns or isoform ratios prove to be altered in specific cancer types, antibody-based detection methods could be developed for diagnostic or prognostic use.

• Therapy response prediction: Since CREBZF expression influences sensitivity to 5-fluorouracil , immunohistochemical assessment of CREBZF in tumor samples might predict treatment response.

• Drug development tools: Antibodies detecting CREBZF and its post-translational modifications could serve as pharmacodynamic biomarkers in drug development, particularly for compounds targeting stress response pathways.

• Personalized medicine approaches: The complex interplay between CREBZF, p53, and chemotherapeutic response suggests potential for stratifying patients based on CREBZF status.

• Monitoring cellular stress: As CREBZF participates in multiple stress response pathways , antibodies detecting its activation or modification states could provide insights into cellular stress status in various pathological conditions.